26
|
Abe K, Abgrall N, Aihara H, Akiri T, Albert JB, Andreopoulos C, Aoki S, Ariga A, Ariga T, Assylbekov S, Autiero D, Barbi M, Barker GJ, Barr G, Bass M, Batkiewicz M, Bay F, Bentham SW, Berardi V, Berger BE, Berkman S, Bertram I, Beznosko D, Bhadra S, Blaszczyk FDM, Blondel A, Bojechko C, Boyd S, Bravar A, Bronner C, Brook-Roberge DG, Buchanan N, Calland RG, Caravaca Rodríguez J, Cartwright SL, Castillo R, Catanesi MG, Cervera A, Cherdack D, Christodoulou G, Clifton A, Coleman J, Coleman SJ, Collazuol G, Connolly K, Curioni A, Dabrowska A, Danko I, Das R, Davis S, Day M, de André JPAM, de Perio P, De Rosa G, Dealtry T, Densham C, Di Lodovico F, Di Luise S, Dobson J, Duboyski T, Dufour F, Dumarchez J, Dytman S, Dziewiecki M, Dziomba M, Emery S, Ereditato A, Escudero L, Esposito LS, Finch AJ, Frank E, Friend M, Fujii Y, Fukuda Y, Galymov V, Gaudin A, Giffin S, Giganti C, Gilje K, Golan T, Gomez-Cadenas JJ, Gonin M, Grant N, Gudin D, Guzowski P, Hadley DR, Haesler A, Haigh MD, Hansen D, Hara T, Hartz M, Hasegawa T, Hastings NC, Hayato Y, Hearty C, Helmer RL, Hignight J, Hillairet A, Himmel A, Hiraki T, Holeczek J, Horikawa S, Huang K, Hyndman A, Ichikawa AK, Ieki K, Ieva M, Ikeda M, Imber J, Insler J, Ishida T, Ishii T, Ives SJ, Iyogi K, Izmaylov A, Jamieson B, Johnson RA, Jo JH, Jonsson P, Joo KK, Jover-Manas GV, Jung CK, Kaji H, Kajita T, Kakuno H, Kameda J, Kanazawa Y, Karlen D, Karpikov I, Kearns E, Khabibullin M, Khanam F, Khotjantsev A, Kielczewska D, Kikawa T, Kilinski A, Kim JY, Kim J, Kim SB, Kirby B, Kisiel J, Kitching P, Kobayashi T, Kogan G, Konaka A, Kormos LL, Korzenev A, Koseki K, Koshio Y, Kowalik K, Kreslo I, Kropp W, Kubo H, Kudenko Y, Kumaratunga S, Kurjata R, Kutter T, Lagoda J, Laihem K, Laing A, Laveder M, Lawe M, Lee KP, Licciardi C, Lim IT, Lindner T, Lister C, Litchfield RP, Longhin A, Lopez GD, Ludovici L, Macaire M, Magaletti L, Mahn K, Malek M, Manly S, Marchionni A, Marino AD, Marteau J, Martin JF, Maruyama T, Marzec J, Masliah P, Mathie EL, Matsumura C, Matsuoka K, Matveev V, Mavrokoridis K, Mazzucato E, McCauley N, McFarland KS, McGrew C, McLachlan T, Messina M, Metelko C, Mezzetto M, Mijakowski P, Miller CA, Minamino A, Mineev O, Mine S, Missert A, Miura M, Monfregola L, Moriyama S, Mueller TA, Murakami A, Murdoch M, Murphy S, Myslik J, Nagasaki T, Nakadaira T, Nakahata M, Nakai T, Nakajima K, Nakamura K, Nakayama S, Nakaya T, Nakayoshi K, Naples D, Nicholls TC, Nielsen C, Nishikawa K, Nishimura Y, O’Keeffe HM, Obayashi Y, Ohta R, Okumura K, Oryszczak W, Oser SM, Otani M, Owen RA, Oyama Y, Pac MY, Palladino V, Paolone V, Payne D, Pearce GF, Perevozchikov O, Perkin JD, Pinzon Guerra ES, Plonski P, Poplawska E, Popov B, Posiadala M, Poutissou JM, Poutissou R, Przewlocki P, Quilain B, Radicioni E, Ratoff PN, Ravonel M, Rayner MA, Reeves M, Reinherz-Aronis E, Retiere F, Rodrigues PA, Rondio E, Rossi B, Roth S, Rubbia A, Ruterbories D, Sacco R, Sakashita K, Sánchez F, Scantamburlo E, Scholberg K, Schwehr J, Scott M, Scully DI, Seiya Y, Sekiguchi T, Sekiya H, Shibata M, Shiozawa M, Short S, Shustrov Y, Sinclair P, Smith B, Smith RJ, Smy M, Sobczyk JT, Sobel H, Sorel M, Southwell L, Stamoulis P, Steinmann J, Still B, Sulej R, Suzuki A, Suzuki K, Suzuki SY, Suzuki Y, Szeglowski T, Szeptycka M, Tacik R, Tada M, Takahashi S, Takeda A, Takeuchi Y, Tanaka HA, Tanaka M, Tanaka MM, Taylor IJ, Terhorst D, Terri R, Thompson LF, Thorley A, Tobayama S, Toki W, Tomura T, Totsuka Y, Touramanis C, Tsukamoto T, Tzanov M, Uchida Y, Ueno K, Vacheret A, Vagins M, Vasseur G, Wachala T, Waldron AV, Walter CW, Wang J, Wark D, Wascko MO, Weber A, Wendell R, Wikström G, Wilkes RJ, Wilking MJ, Wilkinson C, Williamson Z, Wilson JR, Wilson RJ, Wongjirad T, Yamada Y, Yamamoto K, Yanagisawa C, Yano T, Yen S, Yershov N, Yokoyama M, Yuan T, Zalewska A, Zambelli L, Zaremba K, Ziembicki M, Zimmerman ED, Zito M, Żmuda J. T2K neutrino flux prediction. Int J Clin Exp Med 2013. [DOI: 10.1103/physrevd.87.012001 10.1103/physrevd.87.019902] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
27
|
Seah DS, Scott SM, Najita J, Openshaw T, Krag KJ, Frank E, Sohl J, Stadler ZK, Garrett M, Winer EP, Come S, Lin NU. Abstract P2-16-04: Attitudes of metastatic breast cancer patients towards research biopsies. Cancer Res 2012. [DOI: 10.1158/0008-5472.sabcs12-p2-16-04] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: In the era of molecularly targeted therapy, developing an understanding of the molecular basis of cancer is a principal or secondary goal of many research studies. For this reason, studies collecting tissue for research purposes are increasingly common. Understanding patients' attitudes towards research biopsies may lead to improvement in accrual to research biopsy studies.
Methods: Patients with metastatic breast cancer from two academic and two community hospitals completed a self-administered paper survey consisting of 29 questions in clinic to evaluate their willingness to consider providing additional biopsies (additional biopsy performed with a clinically indicated biopsy) and research purposes only biopsies (RPOB) (research biopsy performed as a stand alone procedure).
Results: 160 patients (n = 80 academic, n=80 community) completed the survey, with a response rate of 98%. As expected, demographic variables differed between sites, with patients from academic sites likely to be younger (p = 0.01), more educated (p = 0.002), employed (p = 0.01), have prior trial participation (P <0.001) and have a longer travel time (P <0.0001). 64 (80%) academic patients and 51 (64%) community patients would definitely or probably consider additional biopsies. 42 (53%) academic patients and 40 (50%) community patients would consider RPOB.
In univariate analyses of patients' willingness to have additional biopsies, patients in academic sites were more likely to agree to additional biopsies than those at community sites (RR = 1.2, 95% CI 1.0–1.5, p = 0.03). Statistically significant differences based on demographic characteristics such as age, education, marital status, prior trial participation, number of prior biopsies, and travel time were not observed.
For RPOB, patients having had more prior biopsies were less likely to consider research biopsies (RR = 0.6, 95% CI 0.4–1.0, p = 0.03). The following variables did not reach statistical significance: type of practice, age, education, marital status, prior trial participation, and travel time.
Patients' willingness in both academic and community sites to consider RPOB declined with more invasive biopsies. Although differences were observed, none were statistically significant between academic and community; skin (56%, 65%), bone marrow (30%, 27%), breast (43%, 49%) or liver (24%, 19%).
Of the 13/160 (8%) patients who would not consider additional biopsies, the most common reasons cited included pain or discomfort (n = 8/13, 62%), risk of biopsy (n = 8/13, 62%) and anxiety related to the biopsy (n = 6/13, 46%). Of the 37/160 (23%) patients who would not consider RPOB, the most common reasons cited included pain or discomfort (n = 23/37, 62%), risk of biopsy (n = 15/37, 41%) and inconvenience of the procedure to the patient (n = 13/37, 35%).
Conclusions: The majority of patients in this study indicated they would consider research biopsies, with a larger proportion willing to consider additional biopsies; patients seen at academic hospitals were more likely to consider additional biopsies compared to those seen at community hospitals. Breast cancer patients' willingness to undergo research biopsies may be higher than generally expected by clinicians and may not be the primary barrier to obtaining research biopsies.
Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P2-16-04.
Collapse
|
28
|
Soreca I, Wallace ML, Frank E, Hasler BP, Levenson JC, Kupfer DJ. Sleep duration is associated with dyslipidemia in patients with bipolar disorder in clinical remission. J Affect Disord 2012; 141:484-7. [PMID: 22578889 PMCID: PMC3612347 DOI: 10.1016/j.jad.2012.01.046] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/23/2011] [Revised: 01/15/2012] [Accepted: 01/30/2012] [Indexed: 12/16/2022]
Abstract
BACKGROUND The pathways to increased cardiovascular risk in bipolar disorder include health behaviors, psychosocial stress and long-term medication exposure. However, the evidence that the association between cardiovascular risk factors and bipolar disorder remains significant after controlling for these co-factors suggests that additional important risk factors have yet to be identified. Our hypothesis is that disturbances in the sleep-wake cycle are an important and under-recognized pathway through which affective disorders lead to increased cardiovascular risk. METHODS In patients with bipolar disorder type 1 in clinical remission, we: 1) explored whether sleep disturbance predicted the endorsement of NCEP ATP-III criteria for dyslipidemia, independent of other lifestyle factors and 2) tested the association between low HDL (NCEP-ATP III) and sleep duration measured with actigraphy over an eight-day period. RESULTS Median sleep duration is significantly associated with low HDL. The risk of having low HDL increases by 1.23 with every 30 minutes of reduced sleep time. LIMITATIONS Since sleep patterns in patients with bipolar disorder are variable and irregular, it is possible that other sleep characteristics, not present during the span of our study, or the variability itself may be what drives the increased cardiovascular risk. CONCLUSIONS Sleep characteristics of patients with bipolar disorder in clinical remission are associated with cardiovascular risk. More specifically, sleep duration was associated with low HDL. Clinicians should pay special attention to sleep hygiene in treating individuals with bipolar disorder, even when they are in clinical remission.
Collapse
|
29
|
|
30
|
Schilling Z, Frank E, Magidson V, Wason J, Lončarek J, Boyer K, Wen J, Khodjakov A. Predictive-focus illumination for reducing photodamage in live-cell microscopy. J Microsc 2012; 246:160-7. [PMID: 22429382 PMCID: PMC3582196 DOI: 10.1111/j.1365-2818.2012.03605.x] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
Due to photobleaching and phototoxicity induced by high-intensity excitation light, the number of fluorescence images that can be obtained in live cells is always limited. This limitation becomes particularly prominent in multidimensional recordings when multiple Z-planes are captured at every time point. Here we present a simple technique, termed predictive-focus illumination (PFI), which helps to minimize cells' exposure to light by decreasing the number of Z-planes that need to be captured in live-cell 3D time-lapse recordings. PFI utilizes computer tracking to predict positions of objects of interest (OOIs) and restricts image acquisition to small dynamic Z-regions centred on each OOI. Importantly, PFI does not require hardware modifications and it can be easily implemented on standard wide-field and spinning-disc confocal microscopes.
Collapse
|
31
|
Rayego-Mateos S, Rodrigues-Diez R, Rodrigues-Diez RR, Lavoz-Barria C, Alique M, Mas S, Pato J, Keri G, Egido J, Ortiz A, Ruiz-Ortega M, Ying L, Tepel M, Frank E, Florian T, Gregor T, Boye J, Maik G, Teng B, Gu C, Haller H, Sever S, Schiffer M, Worthmann K, Leitges M, Dittrich-Breiholz O, Kracht M, Haller H, Schiffer M, Peired A, Angelotti ML, Ronconi E, Lazzeri E, Sisti A, Lasagni L, Romagnani P. Mechanisms and targets of glomerular damage. Nephrol Dial Transplant 2012. [DOI: 10.1093/ndt/gfs229] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
32
|
Frank E, Kupfer DJ, Rucci P, Lotz-Wallace M, Levenson J, Fournier J, Kraemer HC. Simultaneous evaluation of the harms and benefits of treatments in randomized clinical trials: demonstration of a new approach. Psychol Med 2012; 42:865-873. [PMID: 21861951 PMCID: PMC3516402 DOI: 10.1017/s0033291711001619] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Abstract
BACKGROUND One aim of personalized medicine is to determine which treatment is to be preferred for an individual patient, given all patient information available. Particularly in mental health, however, there is a lack of a single objective, reliable measure of outcome that is sensitive to crucial individual differences among patients. METHOD We examined the feasibility of quantifying the total clinical value provided by a treatment (measured by both harms and benefits) in a single metric. An expert panel was asked to compare 100 pairs of patients, one from each treatment group, who had participated in a randomized clinical trial (RCT) involving interpersonal psychotherapy (IPT) and escitalopram, selecting the patient with the preferred outcome considering both benefits and harms. RESULTS From these results, an integrated preference score (IPS) was derived, such that the differences between any two patients' IPSs would predict the clinicians' preferences. This IPS was then computed for all patients in the RCT. A second set of 100 pairs was rated by the panel. Their preferences were highly correlated with the IPS differences (r=0.84). Finally, the IPS was used as the outcome measure comparing IPT and escitalopram. The 95% confidence interval (CI) for the effect size comparing treatments indicated clinical equivalence of the treatments. CONCLUSIONS A metric that combines benefits and harms of treatments could increase the value of RCTs by making clearer which treatments are preferable and, ultimately, for whom. Such methods result in more precise estimation of effect sizes, without increasing the required sample size.
Collapse
|
33
|
Frank E, Frank S. Chairside dental imaging processing with DentalMagic. INTERNATIONAL JOURNAL OF COMPUTERIZED DENTISTRY 2012; 15:327-334. [PMID: 23457902] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/01/2023]
|
34
|
Frank E, Frank S. Computer-assisted periodontal diagnostics using the pa-on periometer and the byzzParo software. INTERNATIONAL JOURNAL OF COMPUTERIZED DENTISTRY 2012; 15:227-235. [PMID: 23252222] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/01/2023]
|
35
|
Frank E, Frank S. Bite registration in Cerec and in lab. INTERNATIONAL JOURNAL OF COMPUTERIZED DENTISTRY 2012; 15:149-158. [PMID: 22891418] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/01/2023]
|
36
|
Filiou MD, Teplytska L, Gormanns P, Reckow S, Zhang Y, Frank E, Kessler MS, Nussbaumer M, Maccarrone G, Landgraf R, Turck CW. Anxiety and mitochondria: Insights from the -omics world. PHARMACOPSYCHIATRY 2011. [DOI: 10.1055/s-0031-1292470] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
37
|
Abe K, Abgrall N, Ajima Y, Aihara H, Albert JB, Andreopoulos C, Andrieu B, Aoki S, Araoka O, Argyriades J, Ariga A, Ariga T, Assylbekov S, Autiero D, Badertscher A, Barbi M, Barker GJ, Barr G, Bass M, Bay F, Bentham S, Berardi V, Berger BE, Bertram I, Besnier M, Beucher J, Beznosko D, Bhadra S, Blaszczyk FDMM, Blondel A, Bojechko C, Bouchez J, Boyd SB, Bravar A, Bronner C, Brook-Roberge DG, Buchanan N, Budd H, Calvet D, Cartwright SL, Carver A, Castillo R, Catanesi MG, Cazes A, Cervera A, Chavez C, Choi S, Christodoulou G, Coleman J, Coleman W, Collazuol G, Connolly K, Curioni A, Dabrowska A, Danko I, Das R, Davies GS, Davis S, Day M, De Rosa G, de André JPAM, de Perio P, Delbart A, Densham C, Di Lodovico F, Di Luise S, Dinh Tran P, Dobson J, Dore U, Drapier O, Dufour F, Dumarchez J, Dytman S, Dziewiecki M, Dziomba M, Emery S, Ereditato A, Escudero L, Esposito LS, Fechner M, Ferrero A, Finch AJ, Frank E, Fujii Y, Fukuda Y, Galymov V, Gannaway FC, Gaudin A, Gendotti A, George MA, Giffin S, Giganti C, Gilje K, Golan T, Goldhaber M, Gomez-Cadenas JJ, Gonin M, Grant N, Grant A, Gumplinger P, Guzowski P, Haesler A, Haigh MD, Hamano K, Hansen C, Hansen D, Hara T, Harrison PF, Hartfiel B, Hartz M, Haruyama T, Hasegawa T, Hastings NC, Hastings S, Hatzikoutelis A, Hayashi K, Hayato Y, Hearty C, Helmer RL, Henderson R, Higashi N, Hignight J, Hirose E, Holeczek J, Horikawa S, Hyndman A, Ichikawa AK, Ieki K, Ieva M, Iida M, Ikeda M, Ilic J, Imber J, Ishida T, Ishihara C, Ishii T, Ives SJ, Iwasaki M, Iyogi K, Izmaylov A, Jamieson B, Johnson RA, Joo KK, Jover-Manas GV, Jung CK, Kaji H, Kajita T, Kakuno H, Kameda J, Kaneyuki K, Karlen D, Kasami K, Kato I, Kearns E, Khabibullin M, Khanam F, Khotjantsev A, Kielczewska D, Kikawa T, Kim J, Kim JY, Kim SB, Kimura N, Kirby B, Kisiel J, Kitching P, Kobayashi T, Kogan G, Koike S, Konaka A, Kormos LL, Korzenev A, Koseki K, Koshio Y, Kouzuma Y, Kowalik K, Kravtsov V, Kreslo I, Kropp W, Kubo H, Kudenko Y, Kulkarni N, Kurjata R, Kutter T, Lagoda J, Laihem K, Laveder M, Lee KP, Le PT, Levy JM, Licciardi C, Lim IT, Lindner T, Litchfield RP, Litos M, Longhin A, Lopez GD, Loverre PF, Ludovici L, Lux T, Macaire M, Mahn K, Makida Y, Malek M, Manly S, Marchionni A, Marino AD, Marteau J, Martin JF, Maruyama T, Maryon T, Marzec J, Masliah P, Mathie EL, Matsumura C, Matsuoka K, Matveev V, Mavrokoridis K, Mazzucato E, McCauley N, McFarland KS, McGrew C, McLachlan T, Messina M, Metcalf W, Metelko C, Mezzetto M, Mijakowski P, Miller CA, Minamino A, Mineev O, Mine S, Missert AD, Mituka G, Miura M, Mizouchi K, Monfregola L, Moreau F, Morgan B, Moriyama S, Muir A, Murakami A, Murdoch M, Murphy S, Myslik J, Nakadaira T, Nakahata M, Nakai T, Nakajima K, Nakamoto T, Nakamura K, Nakayama S, Nakaya T, Naples D, Navin ML, Nelson B, Nicholls TC, Nishikawa K, Nishino H, Nowak JA, Noy M, Obayashi Y, Ogitsu T, Ohhata H, Okamura T, Okumura K, Okusawa T, Oser SM, Otani M, Owen RA, Oyama Y, Ozaki T, Pac MY, Palladino V, Paolone V, Paul P, Payne D, Pearce GF, Perkin JD, Pettinacci V, Pierre F, Poplawska E, Popov B, Posiadala M, Poutissou JM, Poutissou R, Przewlocki P, Qian W, Raaf JL, Radicioni E, Ratoff PN, Raufer TM, Ravonel M, Raymond M, Retiere F, Robert A, Rodrigues PA, Rondio E, Roney JM, Rossi B, Roth S, Rubbia A, Ruterbories D, Sabouri S, Sacco R, Sakashita K, Sánchez F, Sarrat A, Sasaki K, Scholberg K, Schwehr J, Scott M, Scully DI, Seiya Y, Sekiguchi T, Sekiya H, Shibata M, Shimizu Y, Shiozawa M, Short S, Siyad M, Smith RJ, Smy M, Sobczyk JT, Sobel H, Sorel M, Stahl A, Stamoulis P, Steinmann J, Still B, Stone J, Strabel C, Sulak LR, Sulej R, Sutcliffe P, Suzuki A, Suzuki K, Suzuki S, Suzuki SY, Suzuki Y, Suzuki Y, Szeglowski T, Szeptycka M, Tacik R, Tada M, Takahashi S, Takeda A, Takenaga Y, Takeuchi Y, Tanaka K, Tanaka HA, Tanaka M, Tanaka MM, Tanimoto N, Tashiro K, Taylor I, Terashima A, Terhorst D, Terri R, Thompson LF, Thorley A, Toki W, Tomaru T, Totsuka Y, Touramanis C, Tsukamoto T, Tzanov M, Uchida Y, Ueno K, Vacheret A, Vagins M, Vasseur G, Wachala T, Walding JJ, Waldron AV, Walter CW, Wanderer PJ, Wang J, Ward MA, Ward GP, Wark D, Wascko MO, Weber A, Wendell R, West N, Whitehead LH, Wikström G, Wilkes RJ, Wilking MJ, Wilson JR, Wilson RJ, Wongjirad T, Yamada S, Yamada Y, Yamamoto A, Yamamoto K, Yamanoi Y, Yamaoka H, Yanagisawa C, Yano T, Yen S, Yershov N, Yokoyama M, Zalewska A, Zalipska J, Zambelli L, Zaremba K, Ziembicki M, Zimmerman ED, Zito M, Żmuda J. Indication of electron neutrino appearance from an accelerator-produced off-axis muon neutrino beam. PHYSICAL REVIEW LETTERS 2011; 107:041801. [PMID: 21866992 DOI: 10.1103/physrevlett.107.041801] [Citation(s) in RCA: 65] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/13/2011] [Indexed: 05/31/2023]
Abstract
The T2K experiment observes indications of ν(μ) → ν(e) appearance in data accumulated with 1.43×10(20) protons on target. Six events pass all selection criteria at the far detector. In a three-flavor neutrino oscillation scenario with |Δm(23)(2)| = 2.4×10(-3) eV(2), sin(2)2θ(23) = 1 and sin(2)2θ(13) = 0, the expected number of such events is 1.5±0.3(syst). Under this hypothesis, the probability to observe six or more candidate events is 7×10(-3), equivalent to 2.5σ significance. At 90% C.L., the data are consistent with 0.03(0.04) < sin(2)2θ(13) < 0.28(0.34) for δ(CP) = 0 and a normal (inverted) hierarchy.
Collapse
|
38
|
Rucci P, Frank E, Scocco P, Calugi S, Miniati M, Fagiolini A, Cassano G. Treatment-emergent suicidal ideation during 4 months of acute management of unipolar major depression with SSRI pharmacotherapy or interpersonal psychotherapy in a randomized clinical trial. Depress Anxiety 2011; 28:303-9. [PMID: 21308882 PMCID: PMC3079416 DOI: 10.1002/da.20758] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/01/2010] [Revised: 09/11/2010] [Accepted: 09/13/2010] [Indexed: 11/08/2022] Open
Abstract
BACKGROUND To date, few randomized controlled trials (RCTs) of major depression have examined suicidal ideation as an outcome measure. Our aim is to determine the incidence of treatment-emergent suicidal ideation (ESI) and behaviors during the acute phase of treatment with an SSRI antidepressant or interpersonal psychotherapy (IPT) in patients with unipolar major depression. METHODS In a two-site RCT, 291 adult outpatients with nonpsychotic major depression and a Hamilton Depression Rating Scale (HDRS) score ≥15 were randomly allocated to IPT or SSRI. Participants who did not remit with monotherapy received augmentation with the other treatment. ESI was defined as a post-baseline HDRS suicidality item score ≥2 or a post-baseline Quick Inventory of Depressive Symptomatology (QIDS) score ≥2 in patients with a baseline score ≤1. RESULTS Of the 231 participants who had no suicidal ideation at baseline, 32 (13.8%) subsequently exhibited ESI on at least one post-baseline visit. Time to suicidal ideation was significantly longer in patients allocated to SSRI compared to those allocated to IPT (HR = 2.21, 95% CI 1.04-4.66, P = .038), even after controlling for treatment augmentation, benzodiazepine use, and comorbidity with anxiety disorders. Worsening of suicidal ideation occurred in 7/60 patients who had suicidal ideation at baseline. In the large majority of cases, suicidal ideation was successfully managed with the study protocol. CONCLUSIONS In the context of careful monitoring and frequent contact, selective serotonin reuptake inhibitor (SSRI) was associated with a lower risk of ESI than IPT and both SSRI and IPT appeared to be safe treatments for patients with past suicide attempts, none of whom exhibited ESI during the study.
Collapse
|
39
|
Calugi S, Cassano GB, Litta A, Rucci P, Benvenuti A, Miniati M, Lattanzi L, Mantua, Lombardi, Fagiolini A, Frank E. Does psychomotor retardation define a clinically relevant phenotype of unipolar depression? J Affect Disord 2011; 129:296-300. [PMID: 20833434 PMCID: PMC3387566 DOI: 10.1016/j.jad.2010.08.004] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/19/2010] [Revised: 08/03/2010] [Accepted: 08/03/2010] [Indexed: 12/17/2022]
Abstract
BACKGROUND The recognition and assessment of psychomotor retardation may have implications for better definition of the clinical phenotypes of depression. The aim of this study was to assess the clinical correlates of psychomotor retardation endorsed at any time during the patients' lifetime (LPR). METHODS The study sample included 291 patients with non-psychotic major depressive disorder (MDD) participating in the clinical trial, "Depression: The Search for Treatment-Relevant Phenotypes." Psychomotor retardation was measured using a factor derived from the Mood Spectrum Self-Report (MOODS-SR) assessment. Using a pre-defined cut-off score on the lifetime psychomotor retardation (LPR) factor of the MOODS-SR, participants were classified into high and low scorers. Logistic regression analysis was used to evaluate the relationship between LPR and subthreshold bipolarity. RESULTS Compared to low scorers, participants with high scores on the LPR factor had greater severity of depression and more bipolarity indicators. CONCLUSIONS The MOODS-SR appears to be helpful to identify clinical phenotypes of unipolar depression and to highlight the usefulness of a lifetime approach to the assessment of psychopathology in the characterisation of patients with unipolar depression.
Collapse
|
40
|
Frank E. Input devices in the dental environment. INTERNATIONAL JOURNAL OF COMPUTERIZED DENTISTRY 2011; 14:273-280. [PMID: 22141236] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/31/2023]
|
41
|
Frank E, Frank S. Dental e-learning. INTERNATIONAL JOURNAL OF COMPUTERIZED DENTISTRY 2011; 14:155-162. [PMID: 21877382] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/31/2023]
|
42
|
Frank E, Cassano GB, Rucci P, Thompson WK, Kraemer HC, Fagiolini A, Maggi L, Kupfer DJ, Shear MK, Houck PR, Calugi S, Grochocinski VJ, Scocco P, Buttenfield J, Forgione RN. Predictors and moderators of time to remission of major depression with interpersonal psychotherapy and SSRI pharmacotherapy. Psychol Med 2011; 41:151-162. [PMID: 20380782 PMCID: PMC3275416 DOI: 10.1017/s0033291710000553] [Citation(s) in RCA: 108] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
BACKGROUND Although many studies suggest that, on average, depression-specific psychotherapy and antidepressant pharmacotherapy are efficacious, we know relatively little about which patients are more likely to respond to one versus the other. We sought to determine whether measures of spectrum psychopathology are useful in deciding which patients with unipolar depression should receive pharmacotherapy versus depression-specific psychotherapy. METHOD A total of 318 adult out-patients with major depression were randomly assigned to escitalopram pharmacotherapy or interpersonal psychotherapy (IPT) at academic medical centers at Pittsburgh, Pennsylvania and Pisa, Italy. Our main focus was on predictors and moderators of time to remission on monotherapy at 12 weeks. RESULTS Participants with higher scores on the need for medical reassurance factor of the Panic-Agoraphobic Spectrum Self-Report (PAS-SR) had more rapid remission with IPT and those with lower scores on the psychomotor activation factor of the Mood Spectrum Self-Report (MOODS-SR) experienced more rapid remission with selective serotonin reuptake inhibitor (SSRI) pharmacotherapy. Non-specific predictors of longer time to remission with monotherapy included several panic spectrum and mood spectrum factors and the Social Phobia Spectrum (SHY) total score. Higher baseline scores on the 17- and 25-item Hamilton Depression Rating Scales (HAMD-17 and HAMD-25) and the Work and Social Adjustment Scale (WSAS) also predicted a longer time to remission, whereas being married predicted a shorter time to remission. CONCLUSIONS This exploratory study identified several non-specific predictors but few moderators of psychotherapy versus pharmacotherapy outcome. It offers useful indicators of the characteristics of patients that are generally difficult to treat, but only limited guidance as to who benefits from IPT versus SSRI pharmacotherapy.
Collapse
|
43
|
Perlmutter J, Frank E, LeStage B, Esserman L. Abstract P5-07-02: I-SPY 2 Clinical Trial: Advocate Involvement in Protocol, Informed Consent and Patient Support Materials Development. Cancer Res 2010. [DOI: 10.1158/0008-5472.sabcs10-p5-07-02] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: I-SPY 2 is an innovative collaboration to assess 8-12 investigational agents and numerous biomarkers in an adaptive, neoadjuvant clinical trial for patients with locally advanced breast cancer and a high likelihood of recurrence. The first site opened in March 2010, and the trial will eventually open in up to 20 sites and enroll 800 patients. Helping patients understand complex clinical trials and make informed decisions about participating in them continues to be a challenge. In the interest of meeting regulatory requirements and protecting participating institutions, informed consent documents often confuse potential patients rather than inform them. I-SPY 2 investigators engaged advocates to ensure that informed consent documents were as patient friendly as possible, and to provide supplementary materials to assist patients obtain the information a way that meets their individual learning styles and information needs. Methods: A network of over 170 advocates from around the US have been informed about the I-SPY 2 trial through presentations at SABCS, webinars, a website and monthly email updates. About 25 of these advocates, including novice and experienced advocates, provided input into the protocol, informed consent documents and/or patient support materials. A virtual process (email and teleconferences) was used to plan, develop and finalize patient support materials and to review multiple versions of all documents. A survey to assess this collaboration was conducted once the trial launched. It was distributed to 25 advocates and 8 staff/investigators. This survey captured: 1) key contributions made by the advocates; 2) amount of time spent on various activities; and 3) perceptions about success of the process.
Discussion: Seventeen advocates responses were received, with nine of the seventeen involved in each of the three components—protocol, informed consent, and patient support materials. A majority of the advocates spent between 5 and 9 hours reviewing documents plus between 2 and 9 hours on teleconferences. Both advocates and staff believed that a majority of advocates’ suggestions were incorporated into the final material. However, several of the advocate recommendations were rejected by IRBs, although concerns varied by site. Both investigators and advocates felt the process was a successful collaboration that will improve patient experiences and are likely to improve accrual and compliance. In addition to changing the documents themselves, advocate suggestions led to several changes in the trial procedures. For example, the trial uses a two stage consent process—one to obtain tissue for screening and randomization, and a second to enroll in the treatment phase of the trial. Also, procedures have been defined for collecting data about specific reasons patients decline to participate, and informing patients who are found ineligible for the trial and when investigational agents are removed from the trial. Details from the survey provide information about: 1) the types of contributions re likely to result from involving advocates; and 2) how to structure the collaboration to maximize satisfaction and contribution. Future research will assess patients reactions to the materials developed for I-SPY 2.
Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr P5-07-02.
Collapse
|
44
|
Gilbert AM, Olino TM, Houck P, Fagiolini A, Kupfer DJ, Frank E. Self-reported cognitive problems predict employment trajectory in patients with bipolar I disorder. J Affect Disord 2010; 124:324-8. [PMID: 19942294 PMCID: PMC2888870 DOI: 10.1016/j.jad.2009.11.012] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/25/2009] [Revised: 11/03/2009] [Accepted: 11/12/2009] [Indexed: 10/20/2022]
Abstract
BACKGROUND Cognitive impairment in bipolar disorder has been associated with poor functional outcomes. We examined the relation of self-reported cognitive problems to employment trajectory in patients diagnosed with bipolar I disorder. METHODS 154 bipolar I disorder patients were followed for 15-43months at the Bipolar Disorders Center for Pennsylvanians. Using a multinomial logistic regression we examined predictors of employment group including self-reported cognitive problems, mood symptoms, education and age. Cognitive functioning was measured via 4 self-report items assessing memory/concentration at baseline and termination. Employment status was recorded at baseline and termination. Employment was categorized as working (full-time, part-time, homemaker, volunteer) or not working (leave of absence, disability, unemployed, no longer volunteering) at each time point. Patients were categorized as good stable, improving, worsening and poor stable. RESULTS Baseline self-reported concentration problems and years of education significantly predicted employment trajectory. LIMITATIONS Post-hoc analyses of existing clinical data. CONCLUSIONS Self-reported concentration problems assessed in the context of specific areas of functioning may serve as a sensitive predictor of functional outcome in patients diagnosed with bipolar I disorder.
Collapse
|
45
|
Ditzen C, Varadarajulu J, Czibere L, Gonik M, Targosz BS, Hambsch B, Bettecken T, Kessler MS, Frank E, Bunck M, Teplytska L, Erhardt A, Holsboer F, Müller-Myhsok B, Landgraf R, Turck CW. Proteomic-based genotyping in a mouse model of trait anxiety exposes disease-relevant pathways. Mol Psychiatry 2010; 15:702-11. [PMID: 19139748 DOI: 10.1038/mp.2008.146] [Citation(s) in RCA: 33] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
In our biomarker identification efforts, we have reported earlier on a protein that differs in its electrophoretic mobility between mouse lines bred either for high or low trait anxiety. The altered electrophoretic behavior of enolase phosphatase (EP) is now identified to be caused by two single-nucleotide polymorphisms. In both cases, the genetic polymorphism introduces an amino acid change in the protein's sequence resulting in differential mobility on SDS gels. This was shown by recombinantly expressing the two EP isoforms. Functional studies indicate that the EP isoform from the high anxiety mouse line has a lower enzymatic activity than does its low anxiety mouse counterpart. EP is a member of the methionine salvage pathway that is responsible for the synthesis of S-adenosyl-L-methionine, a natural compound with potential antidepressant activities. In addition, it is linked to the polyamine pathway whose members have functions in anxiety/depression-related behaviors. In a freely-segregating F2 panel, both single-nucleotide polymorphisms were significantly associated with locomotion-independent trait anxiety, further supporting a functional role of EP for this phenotype. The study shows that proteomic analysis can reveal genotypic differences relevant for the phenotype. The identified protein alterations, in turn, can expose metabolic pathways pertinent to the behavioral phenotype.
Collapse
|
46
|
Adrian GP, Blumenstock T, Fischer H, Frank E, Gulde T, Oelhaf H, Thomas P, Trieschmann O. Column Amounts and Some Information on the Vertical Distribution of Trace Gases in the Late North Polar Winter 1990. ACTA ACUST UNITED AC 2010. [DOI: 10.1002/bbpc.19920960308] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
47
|
Levenson JC, Frank E, Cheng Y, Rucci P, Janney CA, Houck P, Forgione RN, Swartz HA, Cyranowski JM, Fagiolini A. Comparative outcomes among the problem areas of interpersonal psychotherapy for depression. Depress Anxiety 2010; 27:434-40. [PMID: 20099274 PMCID: PMC4228685 DOI: 10.1002/da.20661] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
Abstract
BACKGROUND Although interpersonal psychotherapy (IPT) is an efficacious treatment for acute depression, the relative efficacy of treatment in each of the four IPT problem areas (grief, role transitions, role disputes, interpersonal deficits) has received little attention. We evaluated the specificity of IPT by comparing treatment success among patients whose psychotherapy focused on each problem area. Moreover, we sought to understand how the patient characteristics and interpersonal problems most closely linked to the onset of a patient's current depression contributed to IPT success. METHODS Patients meeting DSM-IV criteria for an episode of major depressive disorder (n=182) were treated with weekly IPT. Remission was defined as an average Hamilton Rating Scale for Depression 17-item score of 7 or below over 3 weeks. Personality disorders were diagnosed using the Structured Clinical Interview for DSM-IV Personality Disorders. RESULTS Contrary to our prediction that patients whose treatment was focused on interpersonal deficits would take longer to remit, survival analyses indicated that patients receiving treatment focused on each of the four problem areas did not differ in their times to remission. Nor were patients in the interpersonal deficits group more likely to have an Axis II diagnosis. Patients whose treatment focused on role transitions remitted faster than those whose treatment focused on role disputes, after controlling for covariates. CONCLUSION With skillful use of IPT strategies and tactics and with careful medication management where appropriate, patients in this study whose treatment focused on each problem area were treated with equal success by trained IPT clinicians.
Collapse
|
48
|
Miniati M, Rucci P, Benvenuti A, Frank E, Buttenfield J, Giorgi G, Cassano G. Clinical characteristics and treatment outcome of depression in patients with and without a history of emotional and physical abuse. J Psychiatr Res 2010; 44:302-9. [PMID: 19800634 PMCID: PMC2836419 DOI: 10.1016/j.jpsychires.2009.09.008] [Citation(s) in RCA: 63] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/07/2009] [Revised: 08/28/2009] [Accepted: 09/08/2009] [Indexed: 11/29/2022]
Abstract
Clinical features and treatment outcome were compared in depressed outpatients with and without a history of emotional and physical abuse (EPA), including childhood maltreatment. Patients were initially randomized to IPT or SSRI and then augmented with the second treatment if they did not remit with monotherapy. Assessments included the SCID-I, the SCID-II for DSM-IV diagnoses, the HRSD, the QIDS and the Mood Spectrum Self-Report (MOODS-SR). Seventy-eight (25%) patients reported a history of EPA; 60 (76.9%) were women. Patients with a history of EPA did not differ from those without on HRSD scores at baseline, but showed an earlier age at onset of depression and a longer duration of illness. The two groups differed on several mood spectrum factors, namely: 'depressivemood' (15.6+/-4.9 vs. 13.5+/-5.4; p<0.004), 'psychomotorretardation' (11.7+/-4.5 vs. 9.6+/-4.7; p<0.001), 'drugandillness-relateddepression' (1.3+/-1.3 vs. 0.6+/-1.0; p<0.0001), and 'neurovegetativesymptoms' (8.3+/-2.6 vs. 6.9+/-2.9; p<0.0001). Patients with EPA had also a significantly longer time to remission (89 vs. 67days, log-rank test, p=0.035). The need for augmentation treatment was significantly more frequent among patients with EPA than in those without. The present study suggests that patients with a history of EPA show a subtype of depression characterized by poor treatment response and more severe neurovegetative and psychomotor symptoms.
Collapse
|
49
|
Frank E, Kleinjung T, Burger J, Landgrebe M, Eichhammer P, Hajak G, Langguth B. transcranial Direct Current Stimulation (tDCS) in the treatment of chronic tinnitus – results of a pilot study. KLIN NEUROPHYSIOL 2010. [DOI: 10.1055/s-0030-1250967] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
50
|
Frank G, Kleinjung T, Landgrebe M, Vielsmeier V, Steffenhagen C, Burger J, Frank E, Vollberg G, Hajak G, Langguth B. Left temporal low-frequency rTMS for the treatment of tinnitus: clinical predictors of treatment outcome - a retrospective study. Eur J Neurol 2010; 17:951-6. [DOI: 10.1111/j.1468-1331.2010.02956.x] [Citation(s) in RCA: 36] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|